Belluscura Share Discussion Threads

[buywell3] 04/12/2024 18:54

+++++++++++++++++++++ The Problem +++++++++++++++++++++++

A diabetic foot or leg ulcer is an open sore or wound that can develop from poor circulation, diabetic neuropathy (nerve damage), or a diabetic foot infection. These ulcers can also form as a result of peripheral artery disease, a common side effect of diabetes, that causes arteries in the lower extremities to narrow and prevent healthy blood flow.

Ulcers like these are often slow to heal, and may become non-healing wounds that are chronically infected if not treated properly.

Arterial, or ischemic, ulcers typically form on the heels or toes, while neurotrophic ulcers develop on the bottom or soles of the feet. Venous stasis ulcers are sores that appear on the legs.

It is estimated that approximately one out of three people living with diabetes will experience foot ulcers, and of those, half of the ulcers will become so severe that they may lead to amputation.




==================== The Proposed IMO Solution ======================

Foot Ulcer

A hinged cylinder on one side ( bottom ) made out of a surgical grade material which has a flange that will carry on up the ankle approx 100 cm



IMO UVC sterilization of these devices would be the way to go using a portable UVC sterilization booth see conclusions.

so

This would mean polyvinylidene fluoride (PVDF) being used as it can be molded or 3D printed:

AND IS NOT AFFECTED BY UVC UNLIKE OTHER POLYMERS

Materials like stainless steel, aluminum, most types of glass, Teflon (polytetrafluoroethylene), and certain high-performance plastics like polyvinyllidene fluoride (PVDF) are generally considered not to be significantly damaged by UVC sterilization, as they effectively reflect or absorb the UV-C radiation without major degradation; however, prolonged exposure to any material can still cause potential damage depending on the intensity of the UVC light and the specific material composition.

3D printing

PVDF is a popular choice for 3D printing because of its many desirable properties, including its high strength, purity, and resistance to solvents and acids.
It can be printed on a typical desktop 3D printer.
Some recommend printing PVDF at an extrusion temperature of 240–260°C and on a glass bed heated to 100°C.

Molding
PVDF can be injected, molded, or welded. It's commonly used in the chemical, semiconductor, medical, and defense industries



This will be in 2 sizes one for adults feet and one for children sized feet



A diabetic patient with a foot ulcer would typically receive topical oxygen treatment once a day, with the specific frequency depending on the type of topical oxygen therapy device and the severity of the ulcer, but most often it would be applied daily until the wound heals significant


A circular shaped soft surgical grade elastomer seal with a outward conical profile and sloping downwards toward the patients skin , shall be able to slide into a molded groove that can hold the pressure at the ankle end of the boot so as to present a seal after being taped using surgical tape to the patients ankle , this will be a disposable item.


There will be a valve fitted to the cylindrical foot casing to allow attachment of the Oxygen concentrator.




Lower Leg Ulcer

After cleaning and treatment as above

A device again two sizes, adult and child, the length being approx 250cm to 300cm or above ankle to below knee


A hinged on one side cylinder , again in two sizes adult and child, that allows the fitting via a molded groove capable of standing pressure , at each end of the cylinder (which once again is made of a surgical grade material that can be surgically cleaned for repeated use as above) , elastomer disposable seals which are angled sloping towards the leg at each end will be used again secured to the patients skin with surgical tape. Both elastomer seals to be replaced at each cleaning and treatment .

In all probability the surgical device would be treated with UVC in a UVC cleaning booth

A medical cleaning booth that uses UVC light can disinfect instruments and other medical equipment:


UV sterilizer cabinets

These cabinets can disinfect a variety of equipment, including surgical instruments and endoscopes, in about 60 seconds. They have adjustable shelves to disinfect all sides of objects.

Such UVC cabinets would also be suitable for Home care therapy





Conclusions:


For a health organization to adopt such devices there has to be not only a better outcome for the patient --- which in this case would be

1. Better quality of life
2. Avoidance of limb amputation




But also an economic benefit to the healthcare provider --- which using such devices would be

1. Avoidance of the cost of amputation and ongoing specialist homecare costs associated with a limb amputee

2. To be able to surgically clean and reuse the medical device repeatedly to treat hundreds of patients

3. To be able to offset costs to some or all of the equipment used in such wound treatments to Medicare wherever possible.



Hence IMO Belluscura needs to be able to present the complete solution to the problem together with cost savings .

These should show related cost savings and projections over 2 year, 5year and 10 year periods.

Belluscura also need to think about making a UVC sterilization cabinet to specifically accommodate these devices --- it isn't difficult and presents another opportunity.

Or

Do a deal with someone that is already making them

dyor

[buywell3] 03/12/2024 07:25

Ref RNS today:

Low constant pressure oxygen in a contained chamber such as a Boot shaped chamber to contain the foot with an ulcer looks the way to go IMO

A constant pressure maintained within the boot chamber of up to 35mmHg should show efficacy

Diabetic foot ulcers and leg ulcers are becoming quite common

Diabetic foot ulcers affect approximately 1.6 million people in the United States each year.

With Diabetes becoming ever more common due to poor diet and obesity the numbers of people with such foot ulcers looks set to grow.

Prevalence of both diagnosed and undiagnosed diabetes

Among the U.S. population overall, crude estimates for 2021 were:

38.4 million people of all ages—or 11.6% of the U.S. population—had diabetes



Without successful treatment of a foot ulcer often amputation follows

Google AI

How many US diabetics have feet or legs amputated in 2023 ?

AI Overview

According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), around 130,000 people with diabetes in the United States underwent amputations of their feet or legs in 2023.

Key points about diabetic amputations in the US:

Large number:
Diabetes is the leading cause of lower extremity amputations in the US, with a significant number of people with diabetes requiring amputations each year.

Prevalence:
This figure represents a significant portion of the diabetic population in the US.

Prevention focus:
Many organizations emphasize the importance of early detection and proper foot care to prevent diabetic amputations.



Healthcare costs and homecare costs for amputees in becoming a massive financial burden for the US economy

Prevention of an amputation would be a much better outcome for everyone


Amputation Prevention Alliance

Every 3 minutes and 30 seconds in the United States, a limb is amputated due to diabetes.
African American man rubbing sore knee
Amputations are on the rise in the United States—160,000 people with diabetes undergo amputation each year. And 80% of non-traumatic lower limb amputations happen due to diabetes complications.
An individual who has had an amputation has a worse chance of five-year survival than someone with coronary artery disease, breast cancer, and colorectal cancer.

Amputations in the United States are also substantially more prevalent among people of color.
Quite simply, whether or not you have a limb amputated can come down to the color of your skin, how much money you make, and where you live.





The wound care market, valued at $22.5 billion in 2023, is projected to grow at a robust 5.9% CAGR through to 2032, according to a Global Markets Insights report published in 20231, and Belluscura's technology and expertise positions it well to capitalise on this significant market opportunity.



Commenting, Bob Rauker, Chief Executive said:



"Our joint venture with Separation Design Group demonstrates the potential of leveraging our oxygen-based technology across broader therapeutic applications and healthcare challenges, such as addressing an unmet need in the hard-to-heal wounds market, which is valued at over $22 billion today and growing.



"Partnering with a globally recognized medical device company enables us to explore the development and commercialization of this innovative wound care solution by combining our oxygen enrichment technology and expertise with their resources and distribution capabilities."









So perhaps also some kind of adjustable two sided hinged chamber ---- that can also be attached to arms or legs and hands to enable constant pressure pure oxygen from an oxygen concentrator , for several days of continuous oxygen treatment till an improvement and required healing outcome is achieved.

dyor

[mr macgregor] 28/10/2024 15:16

The chairman is Adam Reynolds, formerly of the Yourgene (YGEN) horror show. Bargepole job.

[jaknife] 28/10/2024 13:44

What did you all expect? Belluscura’s management have a track record of inflating expectations to unreasonable levels and then hopelessly failing to meet them!

And, just like leopards don’t change their spots, over-promotional directors who like to keep their snouts in the trough, don’t become paragons of virtue and vanguards of shareholder value overnight!

Common sense should tell you that (a) they don’t have an adequate enough balance sheet, and (b) don’t have reliable enough profits/cash generation to obtain significant debt. And hence yet another placing is incoming.

Rather than the poisonous drip-drip of a placing every 12 months (or is it six?) they should go for a reset and get a chunk in that will definitely see them through to break even.

There is no reasons to be holding in advance of what could be material dilution.

JakNife

(All spelling and grammatical errors deliberately inserted to annoy Oak Tree Man who likes to annoy honest commentators by stealing quotes without proper attribution!)

[maytrees] 28/10/2024 12:35

Thankfully but sadly, I sold last week in expectation of difficult budget.
Still made a small loss though sale of TEK then also, was profitable.
Out of shares now pending the budget.

[owenski] 28/10/2024 09:02

I'd say they'll be raising again and soon.

This dog certainly limps along.

[mr.oz] 28/10/2024 07:05

Long winded rns leaving the main bit to when they hoped you'd got bored and stopped ?

300k left and likely stop gap raise needed

[sharebuyerzero] 21/10/2024 17:23

What a dreadful investment this has been

[bill216] 21/10/2024 14:51

3rd quarter results maybe but I don't think they have to issue them under uk rules.

[sharebuyerzero] 21/10/2024 14:10

Leak ? News coming ?

[jaknife] 27/9/2024 09:41

In the short term the market is a voting machine, in the long term the market is a weighing machine.

[maytrees] 27/9/2024 08:46

Good morning
Why then JackNife recent buys and share price gains?
Is a t/o in the offing perhaps?

I hold.

[jaknife] 26/9/2024 08:33

Let's go through these numbers without the hyperbole ...




P&L
* Revenue up dramatically but still at an overall immaterial level - just $1.3m
* A sensible gross profit margin though of 37.7% (it was negative before)
* Stonkingly high admin expenses. What on earth are they spending money on? I bet that a lot of that is unjustified remuneration.
* An overall operating loss of $6.1m
* After finance costs a loss of $6.5m!
* Revenue would need to increase by a dramatic level of something like $17.3m just for BELL to get to a point where it was at P&L break even!


Balance Sheet
* cash at 30th June was just $0.9m
* net assets are $18.6m of which $10.9m is intangibles
* tangible book value is $7.7m


Cash Flow
* Dreadful!
* Note that a further $1.7m of costs were capitalised directly to the balance sheet
* hence to get to cash flow break even revenue would need to increase to something more like $21.8m


Conclusion
Q3 revenue is forecast at $1.6m and so Q3 would have a large loss as well, hence why they raised $1.92m post balance sheet. They have a sales target of $4.0m for Q4 but (a) they have a track record of missing sales targets, and (b) revenues need to break $10m per quarter to get to a level where the business is break even.

They will need to raise funds again.

JakNife

[sandeep67] 26/9/2024 07:45

looks like big buy order being filled as isn't even buy 100 shares

[brummy_git] 26/9/2024 06:19

Stunning sales growth delivered by Belluscura today - albeit from a small base.

All the commentary & details here.

[owenski] 28/8/2024 08:13

Bell have been a constant disappointment of misses, so it needs to prove itself.

I certainly would not punt money in this when it needs another funding round.

Maybe with funding - and inventory one can assess again at a future point if the sales growth becomes established, however, their products aren't the only game on the market.

[hatfullofsky] 28/8/2024 04:45

From Paul ScottBelluscura (LON:BELL)Up 50% to 16.5p (£28m) - AGM Trading Update [profit warning] - Paul - BLACK/ On fundamentals: AMBER/REDToday's update tells us revenues are accelerating, but then considerably slashes the FY 12/2024 forecast. It's clearly desperate for more funding for both ongoing losses, and the necessary inventory build for higher sales, but tries to gloss over that reality. Punters might get lucky here, but for me the risks are still way too high. We can look at it fresh once the badly needed fundraising (more dilution with CLN's?) has been done. Bizarre to see a blue sky share rise 50% on a profit warning, but that's what has just happened

[dr biotech] 27/8/2024 13:20

As a long term bear of this lot I'm wondering if now is the time for a small punt. As I highlighted earlier their forecasting is woefully optimistic bordering criminally misleading - I have severe doubts about anything management say, but if they are honest and sales were 500k in june and 700k in July then that is decent and does potentially show this lot may be worth something. Probably wouldn't sell now if I had been a holder anyway.

[hatfullofsky] 27/8/2024 13:10

Strange reaction, with the risk of a fundraise on its way but they might now be able to raise at a higher price...

[bill216] 27/8/2024 12:05

If they've sold out stock and have more orders then I hope they can raise bank finance, rather than issue shares, to increase production. The need to increase production to match demand is a nice problem to have but can also be a tricky position to be in. Fingers crossed they manage it carefully. I'm voting in for now.

[stuffee] 27/8/2024 12:03

JakNife

I have sympathy wirh your response.

I have held Bell since its outset and am absolutely fed up weith the Board's continuous over optimistic forecasting of cash, sales and earnings - nearly misleading past statements. Mecifullly the former FD, who was continuing with absurd suggestions for funding, has now been put out to grass.

The Company would earn respect if it produced realistic forecasts and statements; it might then begin to have a decent market rating.

[jaknife] 27/8/2024 11:52

QS99,

"all to play for then...wonder if it will get tipped this week as well following this encouraging RNS?"

What do you see in the RNS that is "encouraging"?

Is it the dishonest tone with which they downgrade revenue forecasts (yet again) whilst trumpeting record revenues for July?

Is it the air of doubt that management leave by *NOT* providing a cash balance figure?

Is it the subtle way that they hint that there isn't enough cash whilst trying to suggest that they're not going to issue yet more shares ("the Company is currently evaluating debt and credit facilities and other options")?

Belluscura is the poster child for over-promising under-delivering management. Their product is not particularly unique and can be obtained from numerous other sources, yet management have tried to create the impression that their product is ground-breaking and unique. The reality is that this is a low margin commodity product that will never generate adequate profits to justify being listing.

Yet another fund raise will be needed.

JakNife

[qs99] 27/8/2024 11:23

Interesting thanks BG

all to play for then...wonder if it will get tipped this week as well following this encouraging RNS?

[smithie6] 27/8/2024 09:57

Brummy

what price were these when you started ramping them ?

80p ?
100p ?